Precore mutant hepatitis B virus-associated fulminant hepatitis during infliximab therapy for rheumatoid arthritis by Hiroko Kuwabara et al.
CASE REPORT
Precore mutant hepatitis B virus-associated fulminant
hepatitis during infliximab therapy for rheumatoid arthritis
Hiroko Kuwabara & Akira Fukuda & Yasuhiro Tsuda &
Yuro Shibayama
Received: 8 February 2010 /Accepted: 15 March 2010 /
# The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract A 73-year-old female, who suffered from rheu-
matoid arthritis for 10 years, developed precore mutant
hepatitis B virus-associated fulminant hepatitis after 1 year
of infliximab therapy and subsequent methotrexate with-
drawal. We emphasize the importance of preemptive
antiviral therapy before starting infliximab administration
and withdrawing immunosuppressive drugs.
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Introduction
Infliximab, a tumor necrosis factor-α (TNF-α) inhibitor,
has become the standard therapy for active rheumatoid
arthritis (RA), but also has influences on bacterial, viral,
and tuberculous infections [1]. In particular, the reactivation
of hepatitis B virus (HBV) is problematic [2] and HBV-
induced fulminant hepatitis following infliximab treatment
has been reported in patients with Crohn’s disease and
Still’s disease [3–6]. Here, we describe an autopsy case of
RA who developed precore mutant HBV-associated fulmi-
nant hepatitis after 1 year of infliximab therapy and
subsequent methotrexate (MTX) withdrawal.
Case report
A 73-year-old female, with a 10-year history of RA, had
been treated with prednisone (5–10 mg/day) and MTX (5–
8 mg/week) for 10 and 6 years, respectively. These were
ineffective, and infliximab (150 mg every 8 weeks, 3 mg/kg)
was added between June 2004 and May 2005, with liver
function tests at each infusion. A pretreatment screening
test showed that HBsAg and HBcAb were positive, and
hepatitis C virus antibody was negative. Liver tests and
images showed no abnormalities. MTX and prednisone
were tapered, and prednisone was withdrawn in April 2005.
An effective clinical improvement of joint disease was
observed, and C reactive protein became normal. After the
eighth infusion of infliximab, the liver function was found to
be abnormal (AST 291 IU/L (normal <40), ALT 331 IU/L
(<40)), and MTX therapy was withdrawn. Her liver function
progressively worsened (AST 1690 IU/L, ALT 1390 IU/L),
and she was admitted to our hospital in June 2005.
On admission, she had jaundice and mild hepatic
encephalopathy. Laboratory data revealed AST 393 IU/L,
ALT 544 IU/L, γGTP 130 IU/L (<30), LDH 364 IU/L
(115∼245), total bilirubin 15.7 mg/dL (<1.0), prothrombin
time 8% (>70), and NH3 168 µg/dL (30∼80). Her
serological status was as follows: HBsAg, HBeAb, and
IgM HBcAb were positive, while HBsAb and HBeAg were
negative. HBV-DNA was present with a level of 4.3 log
copies per milliliter (<2.6) by polymerase chain reaction
assay. HBV was of genotype B and the precore mutant was
100%. She had no HIV and IgM hepatitis A virus
antibodies. An abdominal computed tomography (CT) scan
showed atrophic liver. Therefore, a diagnosis of fulminant
hepatitis due to the reactivation of HBV from a previously
asymptomatic HBV carrier state was made, and lamivudine
(a reverse-transcriptase inhibitor of viral DNA polymerase)
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therapy (150 mg/day) and plasma exchange were immedi-
ately performed. Her condition temporarily improved, and
liver transplantation was considered. However, her liver
function deteriorated and an abdominal CT showed more
atrophic liver. She died of liver failure 18 days after admis-
sion. A postmortem examination was performed, and the
ascites volume was 170 mL. The liver was remarkably
atrophied, weighing just 508 g, and more than 80% of the
hepatocytes were necrotic. CD8-positive cytotoxic T
lymphocytes had predominantly infiltrated, and amyloid A
protein deposition as a result of RA was seen in the hepatic
artery (Fig. 1). Vessels in most organs showed amyloid A
protein deposition.
Discussion
Our case suggests that infliximab treatment induces HBV
precore mutation and the destruction of HBV-infected
hepatocytes by CD8-positive cytotoxic T lymphocytes.
The HBV precore mutation is involved in the pathogenesis
of fulminant hepatitis [7], and the reactivation of a precore
mutant HBV during infliximab therapy has been reported
[8]. TNF-α has antiviral properties by inhibiting the
replication of HBV DNA and mediates apoptosis of
cytotoxic T lymphocytes [9, 10]. TNF-α inhibitors may
induce fulminant hepatitis following the reactivation of
precore mutant HBV and the proliferation of cytotoxic T
lymphocytes. In addition to infliximab, long-term MTX
treatment and subsequent withdrawal may accelerate HBV
reactivation. HBV-positive patients are at increased risk of
fulminant hepatic failure after withdrawing immunosuppres-
sive drugs such as MTX because of the hepatocytic attack
following sudden reaction of the immune system [11].
Preemptive antiviral therapy with lamivudine is recom-
mended as part of infliximab therapy for HBV-positive
patients, even if they have normal liver function or an
undetectable viral load [8, 12]. The delayed onset of
antiviral therapy in our patient may have been responsible
for the fatal outcome. This case shows that infliximab
therapy in an HBV-positive patient with RA can lead to
fulminant hepatitis, possibly through the reactivation of
precore mutant HBV and the proliferation of cytotoxic T
lymphocytes. In addition, this case illustrates the impor-
tance of anti-HBV therapy before starting infliximab
administration and withdrawing immunosuppressive drugs.
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